FSD Pharma Files 6-K Corporate Update
Ticker: QNTM · Form: 6-K · Filed: May 24, 2024 · CIK: 1771885
| Field | Detail |
|---|---|
| Company | Fsd Pharma Inc. (QNTM) |
| Form Type | 6-K |
| Filed Date | May 24, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-update, sec-filing
TL;DR
FSD Pharma dropped a 6-K update, check the press release for deets.
AI Summary
FSD Pharma Inc. filed a Form 6-K on May 24, 2024, to report its corporate activities. The filing includes a press release (Exhibit 99.1) providing a corporate update, though specific details of the update, such as dollar amounts or new developments, are not detailed in the provided text.
Why It Matters
This filing indicates FSD Pharma is providing an update to its shareholders and the market, which could contain material information about its business operations or strategic direction.
Risk Assessment
Risk Level: medium — Form 6-K filings often contain updates that can significantly impact a company's stock price, requiring careful review by investors.
Key Players & Entities
- FSD Pharma Inc. (company) — Registrant
- Nathan Coyle (person) — Chief Financial Officer
- May 24, 2024 (date) — Filing Date
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report on corporate activities of FSD Pharma Inc. for the month of May 2024, including the issuance of a press release.
Who signed this Form 6-K on behalf of FSD Pharma Inc.?
Nathan Coyle, Chief Financial Officer, signed the Form 6-K on behalf of FSD Pharma Inc.
What is the Commission File Number for FSD Pharma Inc.?
The Commission File Number for FSD Pharma Inc. is 001-39152.
Which exhibit is included with this Form 6-K filing?
Exhibit 99.1, a Press Release, is included with this Form 6-K filing.
Does FSD Pharma Inc. file annual reports under Form 20-F or 40-F?
FSD Pharma Inc. indicates it files annual reports under cover of Form 20-F.
Filing Stats: 147 words · 1 min read · ~1 pages · Grade level 9.6 · Accepted 2024-05-24 16:51:38
Filing Documents
- fsd_6k.htm (6-K) — 8KB
- fsd_ex991.htm (EX-99.1) — 15KB
- fsd_ex991img1.gif (GRAPHIC) — 6KB
- 0001654954-24-006918.txt ( ) — 33KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. FSD Pharma Inc. (Registrant) Date: May 24, 2024 By: /s/ Nathan Coyle Nathan Coyle, Chief Financial Officer 2 EXHIBIT INDEX Exhibit Description 99.1 Press Release 3